Ironwood Pharmaceuticals (IRWD) Change in Receivables (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Change in Receivables across 17 years of filings, most recently posting $59.1 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $59.1 million, up 240.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.1 million (up 304.88% YoY), and the FY2025 annual result was -$35.1 million, up 25.59% from the prior year.
• Change in Receivables came in at $59.1 million for Q1 2026 at Ironwood Pharmaceuticals, up from -$73.6 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $59.1 million in Q1 2026 to a low of -$73.6 million in Q4 2025.
• The 5-year median for Change in Receivables is $3.2 million (2023), against an average of -$1.9 million.
• Across the five-year window, Change in Receivables jumped 4405.71% in 2022 and plunged 1395.27% in 2025, its largest moves.
• Ironwood Pharmaceuticals' Change in Receivables stood at -$937000.0 in 2022, then soared by 588.47% to $4.6 million in 2023, then climbed by 24.19% to $5.7 million in 2024, then slumped by 1395.27% to -$73.6 million in 2025, then jumped by 180.27% to $59.1 million in 2026.
• The last three Change in Receivables figures came in at $59.1 million (Q1 2026), -$73.6 million (Q4 2025), and $34.2 million (Q3 2025), per Business Quant data.